

Vivek Subbiah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298288/publications.pdf>

Version: 2024-02-01

453
papers

17,312
citations

25014

57
h-index

20943

115
g-index

461
all docs

461
docs citations

461
times ranked

21838
citing authors

#	ARTICLE	IF	CITATIONS
1	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
2	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
3	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600 Mutant Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 7-13.	0.8	630
4	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
5	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
6	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1916-1927.	13.9	412
7	Selective <i>RET</i> kinase inhibition for patients with <i>RET</i> -altered cancers. <i>Annals of Oncology</i> , 2018, 29, 1869-1876.	0.6	304
8	Precision Targeted Therapy with BLU-667 for <i>RET</i> -Driven Cancers. <i>Cancer Discovery</i> , 2018, 8, 836-849.	7.7	298
9	Dabrafenib plus trametinib in patients with <i>BRAF</i> V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	5.1	297
10	Vemurafenib for <i>BRAF</i> V600 Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	3.4	280
11	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
12	<i>BRAF</i> Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247
13	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	5.1	247
14	Pralsetinib for <i>RET</i> fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222
15	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.	0.4	203
16	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
17	Pralsetinib for patients with advanced or metastatic <i>RET</i> -altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 491-501.	5.5	192
18	<i>RET</i> Solvent Front Mutations Mediate Acquired Resistance to Selective <i>RET</i> Inhibition in <i>RET</i> -Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 541-549.	0.5	189

#	ARTICLE	IF	CITATIONS
19	<i>RET</i> Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clinical Cancer Research, 2017, 23, 1988-1997.	3.2	186
20	State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers. Journal of Clinical Oncology, 2020, 38, 1209-1221.	0.8	172
21	Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer, 2020, 6, 797-810.	3.8	169
22	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	5.1	165
23	The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Annals of Oncology, 2020, 31, 1115-1118.	0.6	161
24	Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporosis International, 2010, 21, 1041-1045.	1.3	159
25	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509.	3.4	154
26	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology, 2016, 27, 795-800.	0.6	150
27	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
28	Structural basis of acquired resistance to selipratinib and pralsetinib mediated by non-gatekeeper RET mutations. Annals of Oncology, 2021, 32, 261-268.	0.6	143
29	Ewing's Sarcoma: Standard and Experimental Treatment Options. Current Treatment Options in Oncology, 2009, 10, 126-140.	1.3	127
30	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	3.2	127
31	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
32	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Annals of Oncology, 2018, 29, 1445-1453.	0.6	103
33	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	12.5	103
34	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology, 2022, 19, 51-69.	12.5	101
35	Advances in Targeting RET-Dependent Cancers. Cancer Discovery, 2020, 10, 498-505.	7.7	96
36	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95

#	ARTICLE	IF	CITATIONS
37	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> -V600-Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	7.7	93
38	FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. <i>Annals of Oncology</i> , 2022, 33, 522-533.	0.6	93
39	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	1.2	90
40	Precision therapy for RET-altered cancers with RET inhibitors. <i>Trends in Cancer</i> , 2021, 7, 1074-1088.	3.8	87
41	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i> -altered cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	0.8	87
42	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909.	1.6	86
43	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. <i>Trends in Cancer</i> , 2020, 6, 181-191.	3.8	82
44	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	2.0	81
45	First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 324-333.	1.2	81
46	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
47	Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 43-51.	3.2	77
48	STUMP unresponsive anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , 2015, 8, 66.	6.9	75
49	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9008-9008.	0.8	75
50	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
51	The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. <i>Oncologist</i> , 2019, 24, 1-3.	1.9	73
52	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2644-2651.	3.2	70
53	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4865-4873.	3.2	68
54	Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. <i>Cancer</i> , 2016, 122, 249-257.	2.0	67

#	ARTICLE	IF	CITATIONS
55	Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. <i>PLoS ONE</i> , 2011, 6, e18424.	1.1	64
56	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 5832-5842.	3.2	64
57	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	3.2	64
58	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. <i>Journal of Hematology and Oncology</i> , 2014, 7, 8.	6.9	63
59	Genomically Driven Tumors and Actionability across Histologies: <i>BRAF</i> -Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 533-547.	1.9	63
60	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	0.8	62
61	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. <i>Trends in Cancer</i> , 2021, 7, 15-28.	3.8	61
62	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015, 89, 76-79.	0.9	58
63	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
64	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015, 26, 1012-1018.	0.6	56
65	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. <i>Trends in Cancer</i> , 2018, 4, 101-109.	3.8	56
66	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021, 96, 102179.	3.4	56
67	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	2.9	54
68	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. <i>Oncotarget</i> , 2014, 5, 2349-2354.	0.8	54
69	Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2541-2546.	1.9	53
70	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	3.2	53
71	Myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement. <i>Leukemia and Lymphoma</i> , 2018, 59, 1672-1676.	0.6	53
72	Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. <i>Annals of Oncology</i> , 2018, 29, 2396-2398.	0.6	52

#	ARTICLE	IF	CITATIONS
73	Resistance to Mammalian Target of Rapamycin Inhibitor Therapy in Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, e415-e415.	0.8	50
74	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.	2.0	50
75	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
76	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
77	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. <i>PLoS ONE</i> , 2014, 9, e89388.	1.1	50
78	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw182.	3.0	49
79	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 109-109.	0.8	49
80	Whole Abdominopelvic Intensity-Modulated Radiation Therapy for Desmoplastic Small Round Cell Tumor After Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 317-326.	0.4	48
81	Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis. <i>Oncoscience</i> , 2014, 1, 167-179.	0.9	48
82	Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. <i>Experimental Hematology</i> , 2008, 36, 1078-1083.	0.2	47
83	The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. <i>Cell</i> , 2020, 180, 9-14.	13.5	45
84	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. <i>ESMO Open</i> , 2020, 5, e000799.	2.0	45
85	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
86	Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. <i>Oncotarget</i> , 2015, 6, 40642-40654.	0.8	45
87	Dose-Modified Oral Chemotherapy in the Treatment of AIDS-Related Non-Hodgkin's Lymphoma in East Africa. <i>Journal of Clinical Oncology</i> , 2009, 27, 3480-3488.	0.8	44
88	Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223. <i>Advances in Experimental Medicine and Biology</i> , 2014, 804, 291-304.	0.8	44
89	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
90	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015, 15, 713.	1.1	43

#	ARTICLE	IF	CITATIONS
91	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. <i>Oncology</i> , 2016, 90, 339-346.	0.9	43
92	Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside. <i>Journal of Clinical Oncology</i> , 2012, 30, e64-e68.	0.8	42
93	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3802-3810.	3.2	42
94	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. <i>Head and Neck</i> , 2021, 43, E7-E12.	0.9	42
95	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021, 26, 588-596.	1.9	42
96	Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 112.	1.2	41
97	MultiplexKRASG12/C13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , 2017, 28, 642-650.	0.6	41
98	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	0.8	41
99	Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. <i>Cancers</i> , 2020, 12, 2307.	1.7	40
100	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018, 132, 391-391.	0.6	40
101	Analysis of <i>MDM2</i> Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	39
102	Progresses Toward Precision Medicine in <i>RET</i> -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6102-6111.	3.2	39
103	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. <i>Diagnostics</i> , 2017, 7, 10.	1.3	38
104	Gastric adenocarcinoma in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2011, 57, 524-527.	0.8	36
105	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. <i>Oncologist</i> , 2018, 23, 360-366.	1.9	36
106	Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing's Sarcoma (EWS/FLI1) and Wilms' Tumor(WT1). <i>PLoS ONE</i> , 2013, 8, e68985.	1.1	35
107	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
108	Phase 1 clinical trials for sarcomas: the cutting edge. <i>Current Opinion in Oncology</i> , 2011, 23, 352-360.	1.1	34

#	ARTICLE	IF	CITATIONS
109	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 973-977.	1.1	34
110	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4027-4034.	3.2	34
111	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , 2020, 5, e000866.	2.0	34
112	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6018-6018.	0.8	34
113	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFR β /c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. <i>Journal of Hematology and Oncology</i> , 2014, 7, 52.	6.9	33
114	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 671-676.	1.9	33
115	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. <i>PLoS ONE</i> , 2014, 9, e93676.	1.1	32
116	Universal Genomic Testing Needed to Win the War Against Cancer. <i>JAMA Oncology</i> , 2016, 2, 719.	3.4	32
117	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. <i>Current Oncology Reports</i> , 2017, 19, 78.	1.8	32
118	The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3616-3616.	0.8	32
119	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31
120	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. <i>Oncotarget</i> , 2013, 4, 153-162.	0.8	31
121	Alpha Emitter Radium 223 in High-Risk Osteosarcoma. <i>JAMA Oncology</i> , 2015, 1, 253.	3.4	30
122	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1595-1601.	1.9	30
123	The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. <i>Npj Precision Oncology</i> , 2021, 5, 48.	2.3	30
124	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. <i>Clinical Breast Cancer</i> , 2014, 14, 468-474.	1.1	29
125	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. <i>Oncology</i> , 2016, 91, 348-353.	0.9	29
126	Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1419-20.	3.3	29

#	ARTICLE	IF	CITATIONS
127	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018, 120, 137-141.	0.9	29
128	A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2014, 5, 95-102.	0.8	29
129	Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach. <i>Journal of Surgical Oncology</i> , 2010, 101, 327-333.	0.8	28
130	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.	2.9	28
131	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	28
132	Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. <i>Experimental Hematology and Oncology</i> , 2014, 3, 23.	2.0	27
133	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018, 20, 37.	1.8	27
134	OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, S349-S350.	0.5	27
135	Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. <i>Annals of Oncology</i> , 2018, 29, 1880-1882.	0.6	27
136	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. <i>European Journal of Cancer</i> , 2020, 136, 176-185.	1.3	27
137	Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to seliperatinib in RET fusion-positive lung cancer. <i>Annals of Oncology</i> , 2021, 32, 817-819.	0.6	27
138	<i>MET</i> aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014, 5, 1837-1845.	0.8	27
139	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
140	A framework for genomic biomarker actionability and its use in clinical decision making. <i>Oncoscience</i> , 2014, 1, 614-623.	0.9	26
141	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	0.8	26
142	Targeted Therapy of Ewing's Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-10.	0.7	25
143	Managing Cancer Care during the COVID-19 Pandemic and Beyond. <i>Trends in Cancer</i> , 2020, 6, 533-535.	3.8	25
144	First-in-human phase 1 study of ETC-159 an oral PORCN inhibitor in patients with advanced solid tumours.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2584-2584.	0.8	25

#	ARTICLE	IF	CITATIONS
145	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	3.2	24
146	Germline <i>PTPRD</i> Mutations in Ewing Sarcoma: Biologic and Clinical Implications. <i>Oncotarget</i> , 2013, 4, 884-889.	0.8	24
147	Debunking the Delusion That Precision Oncology Is an Illusion. <i>Oncologist</i> , 2017, 22, 881-882.	1.9	23
148	Current update on gallbladder carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 2474-2489.	1.0	23
149	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
150	Hallmarks of RET and Co-occurring Genomic Alterations in <i>RET</i> -aberrant Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1769-1776.	1.9	23
151	Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors. , 2018, , .		23
152	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016, 7, 23227-23238.	0.8	23
153	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600E Mutant Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 871-878.	1.9	23
154	Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 863-866.	2.3	22
155	Ewing's sarcoma: overcoming the therapeutic plateau. <i>Discovery Medicine</i> , 2012, 13, 405-15.	0.5	22
156	[90Y]Yttrium Microspheres Radioembolotherapy in Desmoplastic Small Round Cell Tumor Hepatic Metastases. <i>Journal of Clinical Oncology</i> , 2011, 29, e292-e294.	0.8	21
157	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	1.6	21
158	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	3.2	21
159	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017, 4, 47-56.	0.9	21
160	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.	1.3	20
161	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019, 11, 677.	1.7	20
162	Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. <i>JCO Precision Oncology</i> , 2020, 4, 1302-1306.	1.5	20

#	ARTICLE	IF	CITATIONS
163	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
164	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021, 124, 1533-1539.	2.9	20
165	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. <i>Cancers</i> , 2019, 11, 1283.	1.7	19
166	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e19-e26.	0.9	18
167	Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1315.	0.4	18
168	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	0.7	18
169	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020, 150, 90-96.	0.9	18
170	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	1.9	18
171	Radium-223 dichloride therapy in breast cancer with osseous metastases. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211152-bcr2015211152.	0.2	18
172	Exceptional responders: in search of the science behind the miracle cancer cures. <i>Future Oncology</i> , 2015, 11, 1-4.	1.1	17
173	Towards precision oncology in RET-aberrant cancers. <i>Cell Cycle</i> , 2017, 16, 813-814.	1.3	17
174	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.	1.2	17
175	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 5475-5484.	3.2	17
176	Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5830-5842.	3.2	17
177	Intracranial activity of seliprecatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9516-9516.	0.8	17
178	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	0.8	17
179	Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. <i>Pediatric Blood and Cancer</i> , 2010, 54, 180-181.	0.8	16
180	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	16

#	ARTICLE	IF	CITATIONS
181	Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC). <i>Annals of Oncology</i> , 2018, 29, viii645-viii646.	0.6	16
182	Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. <i>ESMO Open</i> , 2019, 4, e000439.	2.0	16
183	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
184	A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. <i>Clinical Cancer Research</i> , 2021, 27, 6366-6375.	3.2	16
185	Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6023-6023.	0.8	16
186	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. <i>BMC Dermatology</i> , 2015, 15, 2.	2.1	15
187	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	1.9	15
188	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2022, 5, e2214046.	2.8	15
189	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
190	Precision Oncology in Sarcomas: Divide and Conquer. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	14
191	Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. <i>Case Reports in Oncology</i> , 2019, 12, 7-13.	0.3	14
192	Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGFR4-KLB Pathway Inhibition. <i>Cancer Discovery</i> , 2019, 9, 1646-1649.	7.7	14
193	A global effort to understand the riddles of COVID-19 and cancer. <i>Nature Cancer</i> , 2020, 1, 943-945.	5.7	14
194	Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338.	1.5	14
195	EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2604-TPS2604.	0.8	14
196	Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 148.	0.4	13
197	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	13
198	Mining Public Databases for Precision Oncology. <i>Trends in Cancer</i> , 2018, 4, 463-465.	3.8	13

#	ARTICLE	IF	CITATIONS
199	223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. <i>ESMO Open</i> , 2020, 5, e000635.	2.0	13
200	The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. <i>BMC Medicine</i> , 2021, 19, 209.	2.3	13
201	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.	2.1	13
202	Assessment of Alectinib vs Ceritinib in <i>ALK</i> -Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. <i>JAMA Network Open</i> , 2021, 4, e2126306.	2.8	13
203	Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2134299.	2.8	13
204	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. <i>Discovery Medicine</i> , 2015, 19, 109-16.	0.5	13
205	Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with <i>WT1</i> mutation: A 46 XY phenotypic female with Frasier syndrome. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1349-1351.	0.8	12
206	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015, 33, 700-709.	1.2	12
207	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	1.6	12
208	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	2.3	12
209	A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2524-2524.	0.8	12
210	Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. <i>Oncoscience</i> , 2015, 2, 187-192.	0.9	12
211	Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. <i>European Journal of Cancer</i> , 2022, 172, 340-348.	1.3	12
212	A Tale of Two Histiocytic Disorders. <i>Oncologist</i> , 2013, 18, 2-4.	1.9	11
213	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
214	Imaging of acute abdomen in cancer patients. <i>Abdominal Radiology</i> , 2020, 45, 2287-2304.	1.0	11
215	Early Response Assessment to Targeted Therapy Using ³ -deoxy- ³ [(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. <i>Diagnostics</i> , 2020, 10, 26.	1.3	11
216	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	2.0	11

#	ARTICLE	IF	CITATIONS
217	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. <i>Oncology Research and Treatment</i> , 2021, 44, 547-556.	0.8	11
218	Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. <i>Cancer Research</i> , 2017, 77, CT091-CT091.	0.4	11
219	Impact of tissue-agnostic approvals for patients with sarcoma. <i>Trends in Cancer</i> , 2022, 8, 135-144.	3.8	11
220	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.	3.2	10
221	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	2.0	10
222	EZH2 inhibition for epithelioid sarcoma and follicular lymphoma. <i>Lancet Oncology</i> , The, 2020, 21, 1388-1390.	5.1	10
223	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	1.6	10
224	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3511-3511.	0.8	10
225	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9069-9069.	0.8	10
226	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF ^{V600} mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9074-9074.	0.8	10
227	Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9035-9035.	0.8	10
228	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
229	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. <i>Annals of Hematology</i> , 2013, 92, 1149-1149.	0.8	9
230	Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly. <i>Current Oncology Reports</i> , 2014, 16, 401.	1.8	9
231	Hypopigmented Skin Lesions After Immunotherapy. <i>JAMA Oncology</i> , 2018, 4, 1118.	3.4	9
232	High-Throughput Architecture for Discovering Combination Cancer Therapeutics. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	9
233	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	9
234	Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. <i>Journal of Alternative and Complementary Medicine</i> , 2020, 26, 346-348.	2.1	9

#	ARTICLE	IF	CITATIONS
235	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. <i>ESMO Open</i> , 2021, 6, 100172.	2.0	9
236	Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with <i>RET</i> -Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. <i>Oncologist</i> , 2022, 27, 13-21.	1.9	9
237	Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	0.8	9
238	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015, 6, 28453-28462.	0.8	9
239	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	0.8	9
240	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	3.5	9
241	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	8
242	Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in Sporadic medullary thyroid carcinoma. <i>Surgery</i> , 2020, 167, 80-86.	1.0	8
243	Testing for COVID-19 in patients with cancer. <i>EClinicalMedicine</i> , 2020, 23, 100374.	3.2	8
244	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 829-835.	1.2	8
245	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 11019-11019.	0.8	8
246	COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 64-66.	0.6	8
247	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. <i>Discovery Medicine</i> , 2014, 18, 331-9.	0.5	8
248	Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutation. <i>Journal of Breast Cancer</i> , 2014, 17, 287.	0.8	7
249	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	2.9	7
250	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 205-213.	0.4	7
251	Of mice and men: lost in translation. <i>Annals of Oncology</i> , 2019, 30, 499-500.	0.6	7
252	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e516.	5.1	7

#	ARTICLE	IF	CITATIONS
253	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
254	Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. <i>Clinical Cancer Research</i> , 2021, 27, 2672-2674.	3.2	7
255	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. <i>ESMO Open</i> , 2021, 6, 100079.	2.0	7
256	Abstract CT111: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies. <i>Cancer Research</i> , 2017, 77, CT111-CT111.	0.4	7
257	Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3520-3520.	0.8	7
258	Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. <i>Oncoscience</i> , 2015, 2, 646-658.	0.9	7
259	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	0.9	7
260	Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3606-3606.	0.8	7
261	Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
262	Adolescent oncology: who cares?â€”the new KID on the block. <i>Supportive Care in Cancer</i> , 2010, 18, 771-773.	1.0	6
263	Fast-tracking novel drugs in pediatric oncology. <i>Cell Cycle</i> , 2015, 14, 1127-1128.	1.3	6
264	Jaundice (Hyperbilirubinemia) in Cancer. <i>JAMA Oncology</i> , 2016, 2, 1103.	3.4	6
265	An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3â€²-deoxy-3â€²-[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. <i>Diagnostics</i> , 2017, 7, 20.	1.3	6
266	Autoimmune hypophysitis. <i>Lancet Oncology</i> , The, 2018, 19, e123.	5.1	6
267	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. <i>Annals of Oncology</i> , 2018, 29, viii33.	0.6	6
268	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	6
269	Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005041.	0.5	6
270	Clinical activity and safety of the RET inhibitor pralsetinib in patients with <i>RET</i> fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3079-3079.	0.8	6

#	ARTICLE	IF	CITATIONS
271	Patient-Reported Outcomes with Selpercatinib Among Patients with <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. <i>Oncologist</i> , 2022, 27, 22-29.	1.9	6
272	Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. <i>Cancer Research</i> , 2018, 78, CT024-CT024.	0.4	6
273	ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E-mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2604-TPS2604.	0.8	6
274	Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11519-11519.	0.8	6
275	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. <i>Discovery Medicine</i> , 2014, 18, 323-30.	0.5	6
276	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	5
277	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 877-885.	1.1	5
278	Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. <i>Oncologist</i> , 2019, 24, 1291-1293.	1.9	5
279	Activity of Brigatinib in Crizotinib and Ceritinib-Resistant <i>ROS1</i> -Rearranged Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	5
280	Exclusion of Older Adults in COVID-19 Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2293-2294.	1.4	5
281	Molecular Imaging with ^{18}F -deoxy- ^{18}F -Fluorothymidine (^{18}F -FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. <i>Diagnostics</i> , 2020, 10, 125.	1.3	5
282	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
283	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021, 39, 1357-1365.	1.2	5
284	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
285	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)., 2021, , .		5
286	Right to Try, expanded access use, Project Facilitate, and clinical trial reform. <i>Annals of Oncology</i> , 2021, 32, 1083-1086.	0.6	5
287	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016, 128, 480-480.	0.6	5
288	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or) <i>TJ ETQq0 0 0 r gBT /Overlock 10 T</i>	0.8	5

#	ARTICLE	IF	CITATIONS
289	Alpha particle radium-223 dichloride ($^{223}\text{RaCl}_2$) in high risk osteosarcoma.. Journal of Clinical Oncology, 2016, 34, 11029-11029.	0.8	5
290	Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.. Journal of Clinical Oncology, 2016, 34, 2528-2528.	0.8	5
291	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 9073-9073.	0.8	5
292	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	0.8	5
293	Bringing wearable devices into oncology practice: fitting smart technology in the clinic. Discovery Medicine, 2018, 26, 261-270.	0.5	5
294	Vandetanib photoinduced cutaneous toxicities. Cutis, 2019, 103, E24-E29.	0.4	5
295	Elevated maternal lipoprotein (a) and neonatal renal vein thrombosis: a case report. Journal of Medical Case Reports, 2008, 2, 106.	0.4	4
296	Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver “ Will it hit the moving target?. Expert Opinion on Investigational Drugs, 2011, 20, 1471-1477.	1.9	4
297	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research, 2017, 23, 4155-4162.	3.2	4
298	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers, 2020, 12, 2636.	1.7	4
299	Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass. Oncology, 2021, 99, 62-64.	0.9	4
300	Effect of lurbinedetin on the QTc interval in patients with advanced solid tumors: an exposure“response analysis. Cancer Chemotherapy and Pharmacology, 2021, 87, 113-124.	1.1	4
301	Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma.. Journal of Clinical Oncology, 2014, 32, TPS10600-TPS10600.	0.8	4
302	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2520-2520.	0.8	4
303	Co-targeting BRAF with mTOR inhibition in solid tumors harboring <i>BRAF</i> mutations: A phase I study.. Journal of Clinical Oncology, 2016, 34, 2517-2517.	0.8	4
304	Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.. Journal of Clinical Oncology, 2017, 35, e14610-e14610.	0.8	4
305	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget, 2018, 9, 28842-28848.	0.8	4
306	Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers, 2021, 13, 5249.	1.7	4

#	ARTICLE	IF	CITATIONS
307	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	1.0	4
308	Rechallenge with anti-EGFR-based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3607-3607.	0.8	4
309	Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, 149-149.	0.8	4
310	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 625-634.	1.9	4
311	Think Globally, Act Locally: Globalizing Precision Oncology. <i>Cancer Discovery</i> , 2022, 12, 886-888.	7.7	4
312	Activity of Pemigatinib in Pilocytic Astrocytoma and <i>FGFR1</i> ^{N546K} Mutation. <i>JCO Precision Oncology</i> , 2022, 6, e2100371.	1.5	4
313	Cognitive Changes During Chemotherapy. <i>JAMA Oncology</i> , 2015, 1, 1353.	3.4	3
314	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017, 92, 14-20.	0.9	3
315	The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 81-81.	1.5	3
316	Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. <i>BMJ Case Reports</i> , 2019, 12, e218839.	0.2	3
317	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. <i>Cancers</i> , 2020, 12, 710.	1.7	3
318	Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9522-9522.	0.8	3
319	18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. <i>Current Problems in Cancer</i> , 2021, 45, 100797.	1.0	3
320	Assessment of tumour-agnostic therapies in basket trials. <i>Lancet Oncology</i> , The, 2022, 23, e7.	5.1	3
321	Review: Ewing sarcoma treatment: a role for bisphosphonates?. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 503-4.	0.3	3
322	Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, 271-277.	0.2	2
323	Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With <i>AKT1_E17K</i> Mutation. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	2
324	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	1.5	2

#	ARTICLE	IF	CITATIONS
325	Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer ^{18}F -deoxy- ^{18}F -fluorothymidine, [^{18}F]-FLT imaging and early response evaluation. <i>BMJ Case Reports</i> , 2019, 12, e218979.	0.2	2
326	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	1.0	2
327	Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8508-8508.	0.8	2
328	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3608-3608.	0.8	2
329	Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3103-TPS3103.	0.8	2
330	Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15150-e15150.	0.8	2
331	Optimizing anti- α body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. <i>Current Problems in Cancer</i> , 2021, 45, 100799.	1.0	2
332	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. <i>Blood</i> , 2014, 124, 635-635.	0.6	2
333	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. <i>Npj Precision Oncology</i> , 2021, 5, 99.	2.3	2
334	A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS584-TPS584.	0.8	2
335	Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?. <i>Clinical Cancer Research</i> , 2022, 28, 3408-3410.	3.2	2
336	^{99m}Tc -sestamibi Scan Differentiates Tumor From Other Contrast Enhancing Tissue in Choroid Plexus Tumors. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 160-162.	0.3	1
337	Case 36-2009: A Man with Cough, Hoarseness, and Abnormalities on Chest Imaging. <i>New England Journal of Medicine</i> , 2010, 362, 961-961.	13.9	1
338	How Watching the Movie <i>Zombieland</i> Helps Treatment of Cancer in Teenagers. <i>Journal of Cancer Education</i> , 2012, 27, 188-191.	0.6	1
339	Headache in a patient with renal cell carcinoma.. <i>European Journal of Internal Medicine</i> , 2016, 32, e3-e4.	1.0	1
340	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e187-e193.	0.9	1
341	Precision oncology: East meets West. <i>International Journal of Cancer</i> , 2018, 142, 1734-1737.	2.3	1
342	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	2.0	1

#	ARTICLE	IF	CITATIONS
343	Tissue is Still the issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, , .	0.6	1
344	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
345	Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.. , 2013, , .		1
346	Abstract 4700: One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. , 2014, , .		1
347	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. <i>Blood</i> , 2013, 122, 3048-3048.	0.6	1
348	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10021-10021.	0.8	1
349	Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic.. <i>Journal of Clinical Oncology</i> , 2012, 30, 364-364.	0.8	1
350	Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 281-281.	0.8	1
351	Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10595-10595.	0.8	1
352	Longitudinal monitoring of <i>BRAF</i> V600E mutation in urinary cell-free DNA of patients with metastatic cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22175-e22175.	0.8	1
353	Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10049-10049.	0.8	1
354	Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11057-11057.	0.8	1
355	Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3022-3022.	0.8	1
356	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1524-1524.	0.8	1
357	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2004-2004.	0.8	1
358	SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2588-2588.	0.8	1
359	A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2579-2579.	0.8	1
360	Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 232-232.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience.. Journal of Clinical Oncology, 2014, 32, 10531-10531.	0.8	1
362	Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. , 2014, , .		1
363	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS2604-TPS2604.	0.8	1
364	Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.. Journal of Clinical Oncology, 2015, 33, 2597-2597.	0.8	1
365	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.. Journal of Clinical Oncology, 2015, 33, 2588-2588.	0.8	1
366	Low frequency <i>KRAS</i> G12/13 mutations in urine cell-free (cf) DNA from patients with <i>BRAF</i> V600E-mutant advanced cancers.. Journal of Clinical Oncology, 2015, 33, 11048-11048.	0.8	1
367	Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform. , 2015, , .		1
368	Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR,VEGFR,RET) in children, adolescents, and young adults with advanced solid tumors. , 2016, , .		1
369	Abstract 3146: Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. , 2016, , .		1
370	Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration. , 2016, , .		1
371	Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types.. Journal of Clinical Oncology, 2017, 35, 2537-2537.	0.8	1
372	Expanding enrollment of underrepresented populations on early phase clinical trials: An analysis of participation among adolescent and young adults (AYA) with advanced cancers on phase I clinical trials.. Journal of Clinical Oncology, 2018, 36, e18714-e18714.	0.8	1
373	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	0.6	1
374	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New England Journal of Medicine, 2008, 358, 743; author reply 743.	13.9	1
375	ROAR trial: which treatment is effective after progression? " Authors' reply. Lancet Oncology, The, 2022, 23, e94.	5.1	1
376	Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research, 2022, 28, 2969-2969.	3.2	1
377	Modifiers of risk for infectious complications of cancer therapy in children: The long road ahead. Pediatric Blood and Cancer, 2007, 49, 3-5.	0.8	0
378	A Friend Request: To Accept or Decline?. Journal of Palliative Medicine, 2010, 13, 465-465.	0.6	0

#	ARTICLE	IF	CITATIONS
379	There Are Still Some Things Money Can't Buy. Journal of Cancer Education, 2011, 26, 395-396.	0.6	0
380	To Ring or Wring the Bell?. Journal of Palliative Medicine, 2011, 14, 968-969.	0.6	0
381	Happy or Unhappy Christmas?. American Journal of Hospice and Palliative Medicine, 2011, 28, 62-62.	0.8	0
382	Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy. Pediatric Blood and Cancer, 2012, 58, 823-824.	0.8	0
383	The Senses and Cancer. Journal of Palliative Medicine, 2016, 19, 467-467.	0.6	0
384	Bone Complications in Patients With Cancer. JAMA Oncology, 2016, 2, 695.	3.4	0
385	Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. Journal of Computer Assisted Tomography, 2018, 42, 357-364.	0.5	0
386	Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designs—The 4P Model. Mayo Clinic Proceedings, 2020, 95, 2566-2568.	1.4	0
387	Advances in cancer research dissemination through the pandemic and beyond. Annals of Oncology, 2021, 32, 689-693.	0.6	0
388	Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. Oncotarget, 2021, 13, 13-15.	0.8	0
389	Analyses of Prognostic Factors for Survival in East African Patients with AIDS-Related Non-Hodgkin's Lymphoma (AR-NHL) Treated with Dose Modified Oral Chemotherapy.. Blood, 2006, 108, 3862-3862.	0.6	0
390	Clinical Features of Patients with T Cell Large Granular Lymphocyte Leukemia Distinguish Patients with Splenomegaly and Those Who Benefit from Splenectomy.. Blood, 2006, 108, 4467-4467.	0.6	0
391	Biotargets in Sarcomas: The Past, Present, and a Look into the Future. , 2012, , 419-438.		0
392	Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. , 2012, , .		0
393	Abstract 2669: Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. , 2012, , .		0
394	Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma.. Journal of Clinical Oncology, 2012, 30, e13020-e13020.	0.8	0
395	Abstract 4387: Molecular profiling for actionable aberrations in advanced osteosarcoma.. , 2013, , .		0
396	Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
397	Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform.. , 2013, , .		0
398	Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.. , 2013, , .		0
399	Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.. , 2013, , .		0
400	c-Met abnormalities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors.. Journal of Clinical Oncology, 2014, 32, 407-407.	0.8	0
401	Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin.. Journal of Clinical Oncology, 2014, 32, 2563-2563.	0.8	0
402	Local and systemic antitumor effects of activated autologous dendritic cells for intratumoral injection: A phase I/II trial.. Journal of Clinical Oncology, 2014, 32, TPS3133-TPS3133.	0.8	0
403	A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.. Journal of Clinical Oncology, 2014, 32, 2576-2576.	0.8	0
404	Genomic profiling and precision medicine in 3,745 patients with advanced cancer.. Journal of Clinical Oncology, 2014, 32, e13521-e13521.	0.8	0
405	BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla).. Journal of Clinical Oncology, 2014, 32, e22139-e22139.	0.8	0
406	A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2628-TPS2628.	0.8	0
407	Clinical next-generation sequencing to identify actionable alterations in a phase I program.. Journal of Clinical Oncology, 2014, 32, 11115-11115.	0.8	0
408	A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2639-TPS2639.	0.8	0
409	Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine.. Journal of Clinical Oncology, 2014, 32, e22154-e22154.	0.8	0
410	Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center.. Journal of Clinical Oncology, 2014, 32, e21024-e21024.	0.8	0
411	Abstract LB-170: Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. , 2014, , .		0
412	Abstract 5080: Clinical next generation sequencing of adolescents and young adult (AYA) patients with cancer reveals aggressive biology: A preliminary report from a major cancer center. , 2014, , .		0
413	Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. Journal of Clinical Oncology, 2015, 33, 605-605.	0.8	0
414	Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.. Journal of Clinical Oncology, 2015, 33, 320-320.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with <i>BRAF</i>-mutant advanced cancer.. Journal of Clinical Oncology, 2015, 33, 105-105.	0.8	0
416	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584.	0.8	0
417	Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials of targeted therapies.. Journal of Clinical Oncology, 2015, 33, 2581-2581.	0.8	0
418	Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. , 2015, , .		0
419	Abstract 2499: Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers. , 2015, , .		0
420	Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers. , 2015, , .		0
421	Abstract 604: Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. , 2015, , .		0
422	Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy.. Journal of Clinical Oncology, 2016, 34, e21637-e21637.	0.8	0
423	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. Journal of Clinical Oncology, 2016, 34, 2546-2546.	0.8	0
424	Symptom clusters in patients with advanced cancer in an early-phase clinical trials clinic.. Journal of Clinical Oncology, 2016, 34, 2540-2540.	0.8	0
425	Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.. Journal of Clinical Oncology, 2016, 34, 2573-2573.	0.8	0
426	Clinical utilization of precision oncology decision support for genomically-informed cancer therapy.. Journal of Clinical Oncology, 2016, 34, 11605-11605.	0.8	0
427	Clinical next-generation sequencing in sarcomas.. Journal of Clinical Oncology, 2016, 34, 11046-11046.	0.8	0
428	Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response. , 2016, , .		0
429	Abstract B005: Cytokine production by intratumorally administered activated dendritic cells correlates with survival in a Phase I clinical trial in diverse cancers. , 2016, , .		0
430	Personalized Medicine in Hereditary Cancer Syndromes. , 2017, , 199-225.		0
431	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. Journal of Clinical Oncology, 2017, 35, 11019-11019.	0.8	0
432	Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies.. Journal of Clinical Oncology, 2017, 35, TPS2603-TPS2603.	0.8	0

#	ARTICLE	IF	CITATIONS
433	Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 11567-11567.	0.8	0
434	Clinical next generation sequencing for precision oncology in rare cancers.. Journal of Clinical Oncology, 2017, 35, 2582-2582.	0.8	0
435	Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors.. Journal of Clinical Oncology, 2017, 35, e14042-e14042.	0.8	0
436	Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.. Journal of Clinical Oncology, 2017, 35, 2583-2583.	0.8	0
437	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.. Journal of Clinical Oncology, 2017, 35, 2526-2526.	0.8	0
438	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 11551-11551.	0.8	0
439	Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials.. Journal of Clinical Oncology, 2017, 35, 10034-10034.	0.8	0
440	Abstract CT097: Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic targeting P-cadherin, in advanced solid tumors. , 2017, , .		0
441	Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials. , 2017, , .		0
442	Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers. , 2017, , .		0
443	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
444	Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials.. Journal of Clinical Oncology, 2017, 35, 152-152.	0.8	0
445	Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment.. Journal of Clinical Oncology, 2018, 36, 67-67.	0.8	0
446	Analysis of patient related and trial related factors leading to non-participation of patients with advanced cancer in immunotherapy clinical trials: Implications for modifying eligibility criteria.. Journal of Clinical Oncology, 2018, 36, e15066-e15066.	0.8	0
447	TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes.. Journal of Clinical Oncology, 2018, 36, 12052-12052.	0.8	0
448	A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.. Journal of Clinical Oncology, 2018, 36, 2541-2541.	0.8	0
449	Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 886-888.	2.3	0
450	Role of Sodium Fluoride-PET in Primary Bone Tumors. , 2020, , 69-76.		0

#	ARTICLE	IF	CITATIONS
451	Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials.. Journal of Clinical Oncology, 2022, 40, 577-577.	0.8	0
452	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discovery Medicine, 2015, 19, 101-8.	0.5	0
453	Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer. Cancer Research, 2022, 82, OT2-01-02-OT2-01-02.	0.4	0